215649-70-0

Basic information

• Product Name: 2-(2-HYDROXYETHYLAMINO)-N-(3-CHLOROPHENYL)ACETAMIDE
• Synonyms: 2-(2-HYDROXYETHYLAMINO)-N-(3-CHLOROPHENYL)ACETAMIDE;AcetaMide,N-(3-chlorophenyl)-2-[(2-hydroxyethyl)aMino]-
• CAS NO: 215649-70-0
• Molecular Formula: C₁₀H₁₃ClN₂O₂
• Molecular Weight: 228.67542
• Mol File: 215649-70-0.mol

Chemical Properties

• Boiling Point: 470.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.315±0.06 g/cm3(Predicted)
• PKA: 13.54±0.70(Predicted)
• CAS DataBase Reference: 2-(2-HYDROXYETHYLAMINO)-N-(3-CHLOROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-HYDROXYETHYLAMINO)-N-(3-CHLOROPHENYL)ACETAMIDE(215649-70-0)
• EPA Substance Registry System: 2-(2-HYDROXYETHYLAMINO)-N-(3-CHLOROPHENYL)ACETAMIDE(215649-70-0)

Safety Data

• Hazardous Substances Data: 215649-70-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Hydroxyethylamino)-N-(3-chlorophenyl)acetamide is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its unique structure allows it to be a key component in the development of new therapeutic agents.
Used in Enzyme and Protein Inhibition:
2-(2-Hydroxyethylamino)-N-(3-chlorophenyl)acetamide is used as an inhibitor of specific enzymes and proteins in biological systems. Its ability to interact with these targets makes it a valuable tool in the study and treatment of various diseases and conditions.

Upstream product

• 108-42-9 3-chloro-aniline 
• 2564-05-8 2-chloro-N-(3-chlorophenyl)acetamide 
• 141-43-5 ethanolamine 

Downstream Products

• 183499-57-2 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone 
• 253862-99-6 N¹-(3-chlorophenyl)-N²-{[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl}-N²-(2-hydroxyethyl)glycinamide 
• 183500-94-9 1-(3-chlorophenyl)-2-piperazinone hydrochloride 

Relevant articles and documents

Synthesis and cytotoxicity evaluation of some novel 1-(3-Chlorophenyl) piperazin-2-one derivatives bearing imidazole bioisosteres

A series of substituted 3-chlorophenylpiperazinone derivatives were synthesised using L-778123 (an imidazole-containing FTase inhibitor) as a model by bioisosteric replacement of the imidazole ring. The final compounds were evaluated against two human cancer cell lines including A549 (lung cancer) and HT-29 (colon cancer) by MTT assay. The results showed that substitution of imidazole ring with 1-amidinourea, semicarbazide, and thiobiuret led to improvement of cytotoxic activity against both cell lines.

Preparation of a clinically investigated ras farnesyl transferase inhibitor

The synthesis of ras farnesyl-protein transferase inhibitor 1 is described on a multi-kilogram scale. Retrosynthetic analysis reveals chloromethylimidazole 2 and a piperazinone 3 as viable precursors. The 1,5-disubstituted imidazole system was regioselectively assembled via an improved Marckwald imidazole synthesis. A new imidazole dethionation procedure has been developed to convert the Marckwald mercaptoimidazole product to the desired imidazole. This methodology was found to be tolerant of a variety of functional groups providing good to excellent yields of 1,5-disubstituted imidazoles. A new Mitsunobu cyclization strategy was developed to prepare the arylpiperazinone fragment 3.

Efficient synthesis of N-arylpiperazinones via a selective intramolecular Mitsunobu cyclodehydration

A practical two pot synthesis of N-arylpiperazinones from the corresponding aniline is described. The key transformation is a selective intramolecular Mitsunobu cyclodehydration of an amidoalcohol intermediate. A series of N-arylpiperazinones were prepared in yields up to 89%.